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Abstract
Background 5-Fluorouracil remains widely used in
colorectal cancer treatment more than 40 years after its
development. 19F magnetic resonance spectroscopy can be
used in vivo to measure 5FU’s half-life and metabolism to
cytotoxic fluoronucleotides. Previous studies have shown
better survival associated with longer 5FU tumour half-life.
This work investigated 5FU pharmacokinetics in liver
metastases of colorectal cancer.
Methods A total of 32 subjects with colorectal cancer
undergoing 5FU treatment, 15 of whom had liver metas-
tases, were examined in a 1.5T MRI scanner, using a large
coil positioned over the liver. Non-localised spectra were
acquired in 1-min blocks for 32 min after injection of a
5FU bolus. The 5FU half-life was measured in each sub-
ject, and averaged spectra were examined for the presence
of fluoronucleotides. Associations with progression-free
survival were assessed.
Results No association was observed between 5FU half-
life, tumour burden and survival. Half-lives were all shorter
than those associated with improved survival in the liter-
ature. Remarkably, in the group with liver metastases, high
levels of fluoronucleotides were associated with poorer
survival; this counterintuitive result may be due to the
higher levels of fluoronucleotides (whose level is higher in
tumour tissue than in normal liver) in patients with higher
tumour burdens.
Conclusions It is recommended that future studies use
chemical shift imaging at higher field strengths to better
resolve tumour from normal liver. Non-localised spec-
troscopy retains prognostic potential by enabling straight-
forward detection of fluoronucleotides, which are present at
very low concentrations distributed throughout the tissue.
Keywords 19F  Magnetic resonance spectroscopy 
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Introduction
5-Fluorouracil (5FU), after several decades of use, is still
one of the most widely used cytotoxic agents for the
treatment of several cancers including colorectal cancer.
5FU- based chemotherapy improves overall and disease-
free survival of patients with resected stage III colorectal
cancer. Over the last 20 years, the regimes of treatment
have been modified at intervals either by changing the way
the dose is given (bolus or infusion) or by combining it
with different modulators such as leucovorin to enhance
effectiveness. In addition, combination of 5FU with newer
chemotherapies (e.g. irinotecan or oxaloplatin) has signif-
icantly improved the response rates (see for instance, this
recent review [1]). However, still only 40–50% of patients
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respond to 5FU treatment, and the search for new thera-
peutic strategies is continuing.
After injection, 5FU is rapidly metabolised by two
main pathways: the major end-product is fluoro-b-alanine
(FBAL), which is non-toxic; a smaller proportion is me-
tabolised to toxic 5-fluoronucleotides (FNuct), primarily in
tumour cells but also to a lesser extent in normal liver cells,
which express low levels of the required enzymes. 5FU
treatment is uniquely suited to monitoring by 19F magnetic
resonance spectroscopy (MRS) for several reasons: because
the MRS sensitivity of fluorine is very high, because there is
no natural background signal, and because MRS can dis-
tinguish the parent drug from its active and inactive
metabolites in vivo and with time resolution adequate for
pharmacokinetic analysis of the drug metabolism.
In the search for predictive biomarkers of response to
5FU treatment, several clinical studies have been per-
formed [2–6]. It has been reported [2] that in some
patients with liver metastases (whom they termed ‘‘trap-
pers’’), 5FU appears to be retained longer (t[ 20 min)
in tumours than in normal tissues and that 5FU trapping is
correlated with response; in other studies, however, no
trapping or correlation between half-life and response was
seen [7, 8].
In principle, the most attractive potential parameter for
the prediction of response to 5FU would appear to be direct
detection of the toxic fluoronucleotide species (FNucts) in
the tumour. FNuct signals were detected in the first MRS
studies of 5FU in mouse tumours [9], and subsequent
studies in animal and human tumour xenografts have
shown that FNuct predicts response to 5FU treatment
[10–12]. Recent in vivo and ex vivo rodent studies have
detected FNuct in both tumour tissue and normal liver [13].
Although there have been a number of reports of FNuct
detection in tumours in patients [7, 14] it has proved to be
extremely difficult to measure them routinely. To our
knowledge, no clinical studies have addressed whether the
toxic metabolites formed from 5FU in vivo are correlated
with response to treatment.
We have found that by summation of a time series of
19F MRS spectra, it is possible to detect fluoronucleotide
signals in the livers of many patients treated with 5FU. In
the present study, we have used this method to monitor
5FU metabolism in 32 patients with colorectal cancer to
see whether the formation of fluoronucleotides correlated
with clinical response. A novel spatial analysis was then
developed to estimate the proportion of the detected signal
due to metastases. The hepatic fluoronucleotide levels
detected in each individual patient were then correlated
with progression-free survival and with the volume of liver
metastasis. A small cohort of patients underwent two scans,
one breathing room air and one breathing carbogen
(95%O2/5%CO2) for 5 min to investigate any alteration of
the 5FU kinetics resulting from carbogen breathing, a gas
breathing challenge that could potentially improve drug
delivery to tumours [10].
Patients and methods
This research was carried out with informed consent from
the patients and with full local ethics committee approval
(Wandsworth Health Authority). Patients with histologi-
cally proven colorectal carcinoma, for whom chemother-
apy was planned, were eligible for referral by the
consulting clinician. Of the 32 patients enrolled, 18 were
men and 14 were women, mean age 66 years, range
37–85 years. The primary focus was on patients with
metastatic liver disease, but patients free from metastatic
disease receiving 5FU in an adjuvant role were also studied
to characterise 5FU metabolism in normal liver. Fifteen of
32 subjects had liver metastases. The scans were taken
between 1999 and 2004.
Chemotherapy
Patients were prescribed 5FU-containing regimens as a
single agent with modulation by leucovorin. The 5FU was
administered either as a single bolus each day for 5 days
(MAYO regimen), as a weekly bolus, or on the de Gramont
regimen that involves a loading bolus dose of 5FU fol-
lowed by a 48-h infusion. Whichever the regimen, the
patients received a bolus of 5FU (400–425 mg/m2) during
the MR examination. Chemotherapy was prescribed either
for the treatment of existing metastatic disease or as
adjuvant therapy immediately after initial colorectal sur-
gery to prevent the development of metastases.
Carbogen breathing
A small cohort of patients (n = 9) underwent two scans at
3–7 days apart. On the first scan, the bolus was adminis-
tered while the patient was breathing room air freely. On
the second scan, the patient was asked to breathe carbogen
(95% O2/5%CO2) delivered at 30 l min
-1 through a mask
for 5 min, starting 3 min before the 5FU bolus delivery
was initiated, and then subsequently air. This component of
the study was designed to investigate any alteration of the
5FU kinetics resulting from carbogen breathing and thus
the potential of carbogen for enhancing 5FU potency.
Response
Clinical response was assessed as progression-free survival
(PFS) by the attending Medical Oncologist; this was
defined as the time until the patient showed disease
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progression or died. At this point, the treatment of sur-
viving patients was either stopped or switched to another
regimen.
19F MRS
19F MRS and MR imaging were performed on a clinical
1.5T MR system (Signa: GE, Milwaukee, USA) with a
dual-tuned 1H/19F surface coil (20 by 16 cm). The coil was
semi-flexible and allowed conformation to the curvature of
the chest for optimal coverage of the liver. Coronal and
axial gradient echo images were first acquired to confirm
correct positioning of the coil over the patient’s liver. For
patients found to have liver metastases, a respiratory-gated
T2-weighted axial fast spin-echo sequence was used to
localise the metastases. A fluorinated silicone oil reference
sample situated at the coil centre was used to calibrate the
19F pulse power for each patient and to provide a reference
signal for quantitative comparison of data between differ-
ent patients. 19F spectra were acquired using a 90 pulse at
the coil centre with a 500-ms repetition time, 16-kHz
bandwidth and 1024 or 2048 data points. Thirty-two
averages with the reference signal on resonance were first
acquired. The spectrometer frequency was then offset to
observe the 5FU signal on resonance. As the bolus i.v
administration of 5FU was started, spectral acquisitions
were begun and acquired continuously for 32 min in 1-min
blocks. Administration of 5FU lasted typically 1 min, fol-
lowed by a bolus of leucovorin (20 mg/m2). 5FU was
administered by a nurse who remained in the magnet room
during the examination; for the cohort breathing carbogen
during 5FU administration, the nurse also removed the
patient’s mask to allow free breathing of room air once the
carbogen breathing was complete.
Data analysis
5FU data were analysed in the time-domain MRS fitting
package jMRUI [15, 16]. Data were averaged in 2-min
block to give 16 time points. 5FU half-lives were evaluated
by non-linear fitting of data points starting from the highest
point reached, typically in the second block of data.
Additionally, all spectra for a given patient were added
together to give an average spectrum for the full time
course. This average spectrum was assessed for the pres-
ence of FNuct (which is rarely present in concentrations
high enough to be detected in any single 2-min block and
often not detectable even in the average spectrum). Aver-
age spectra in which the SNR for FNuct from the jMRUI
analysis was greater than 2.5 were defined to be FNuct
positive. An example is shown in Fig. 1a, together with an
example time course stack plot in Fig. 1b. Additionally,
FNuct was assessed semi-quantitatively by calculating the
ratio of the FNuct peak area to the largest 5FU peak area
observed from the individual spectra, thus normalising the
FNuct peak area independently of the 5FU half-life. This
semi-quantitative parameter represents the FNuct AUC
normalised to the peak 5FU and depends on the peak FNuct
concentration as well as the time constants of FNuct syn-
thesis and breakdown.
MRI tumour volume and MRS sensitivity analysis
Image data were analysed using a program custom-written
in MATLAB 7.4 (The Mathworks, Inc, Natick, MA) that
numerically simulated the sensitivity of the 19F spectros-
copy coil. The coil was located on the images by its
internal position marker consisting of a tube of water.
ROIs were drawn delineating any visible metastases and
all of the liver tissue visible within the field of view of the
Fig. 1 a Example of summed time course data from subject A,
showing 5FU, the main catabolite FBAL, and an easily detectable
peak from the cytotoxic FNuct. Frequencies are referenced to 5FU at
0 ppm. b 19F MRS time course stack plot from subject P. Data
averaged in 2-min blocks. FNuct is not visible in individual spectra,
but the 5FU bolus and metabolism to FBAL are clear
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coil, from which ROI volumes were calculated. The coil
sensitivity was computed at every voxel within each ROI.
We then calculated the ratio of the metastasis volume
(summed over all the metastasis ROIs) to the total liver
volume, weighted voxelwise according to the 19F MRS
coil sensitivity. We refer to this ratio within this paper as
the fractional metastasis signal (FMS); this measure rep-
resents the fraction of detected 19F signal from metastases,
assuming the metabolites to be uniformly distributed. The
higher the FMS, the more likely that the 19F measure-
ments and kinetics are representative of the tumour
(see Table 2).
Statistical analysis was carried out in GraphPad Prism
5.01 (GraphPad Software, San Diego, CA).
Results and discussion
5FU half-life
The half-life of 5FU in the full patient cohort (n = 32) was
8.0?/-0.48 min (mean ?/-SEM), and the range was
4.0–15.5 min (see Table 1). None of the patients we
studied had a 5FU half-life of longer than 20 min, and
therefore none would be defined as a 5FU ‘‘trapper’’ in the
terminology of Presant et al [2]. No statistical correlation
was observed between PFS and 5FU half-life, either in the
whole population or in the population with detectable
hepatic metastases (P = 0.31, R2 = 0.04 and P = 0.18,
R2 = 0.13, respectively).
Paired survival curves were analysed for the relationship
between progression-free survival and the presence of liver
metastases. As would be expected, the PFS was signifi-
cantly longer in the group of patients without liver
metastases (P = 0.001, Fig. 2a). Patients with and without
liver metastases have been considered separately for the
rest of the analysis to avoid any confounding effects from
this variation in PFS and to investigate the significance of
spectroscopic data in understanding the therapy of metas-
tases. Retrospectively, we decided to investigate the pro-
portion of tumour in the liver in a subset of patients where
the volumes of the metastases were assessed from the
images taken prior to the 5FU bolus. The purpose of this
was twofold: to investigate whether the signal from the
metastasis was overwhelmed by the signal from the liver
(thus masking the half-life of 5FU in the tumour tissue) and
to investigate correlations between tumour volume and
pharmacokinetic parameters.
MRI volume data (see ‘‘Methods’’ for details) were
available for 16 subjects, 11 of whom had been clinically
reported to have liver metastases and one to have liver
cysts. Data were uninterpretable due to motion in 2 cases
(1 reported to have metastases). Data were analysed for the
remaining 14 subjects, and metastasis detection was con-
sistent with the clinical report in all cases. For the 10
subjects with metastases, the FMS varied from 0.05 to 0.52
(mean 0.21, standard deviation 0.17). It should be noted
that this group did not include the two patients with
metastases who survived for longer than 5 months.
Both quantifiable 19F MRS and quantifiable MRI were
available for all these 14 subjects. Although none of them
(like the other patients we studied) had a 5FU half-life long
enough ([20 min) to be defined as a 5FU ‘‘trapper’’ [2], we
still investigated whether there was a correlation between
the relatively short half-lives that we measured and the
hepatic metastatic load. If the metastases had trapped 5FU
and hence had a longer 5FU half-life than normal liver, this
should have given a correlation between FMS and the half-
life measured by MRS. Notably, the two subjects with the
highest FMS values of 0.49 and 0.52 had relatively long
half-life values of 15.5 and 9.4 min (Table 2), with the
other subjects showing half-life values ranging from 4.9 to
11.8 min. However, there was no significant correlation
between FMS and the half-life of 5FU (R2 = 0.40,
P = 0.25). The other 8 subjects with metastases had values
ranging from 0.05 to 0.27 (mean 0.14, standard deviation
0.09).
Interpretable MRI data were not available for all
patients with liver metastases, including the patients with
the longest PFS; nevertheless, some useful inferences can
be drawn from the available data. In the majority of the 14
subjects whose data could be analysed, the metastases
represented a small proportion of the sensitive volume of
the coil (FMS \0.3 in 8/10 patients with metastases, see
Table 2), and therefore it is likely that the MRS data will
be dominated by the kinetics of the metabolites in normal
liver if their concentrations approach those in the tumours.
There is no statistical relationship between metastatic load
and 5FU half-life in this group, which is perhaps to be
expected, since the patients where the metastases are the
source of even half the signal are suffering a very high
disease burden and are not responding to treatment, thus
would not be expected to fall into the group of patients
showing long 5FU half-lives. Conversely, the group
with smaller metastases may have tumour kinetics that
were undetectable against the background normal liver
metabolism.
Since there was evidence from animal studies (for
example, McSheehy et al [10]; Kamm et al [17]) that
carbogen (95%O2/5%CO2) breathing could increase the
uptake of 5FU into the liver metastases, we also invited
several of the patients (n = 9) to attend scanning twice,
once breathing air during 5FU infusion and once breathing
carbogen (see also Table 1). However, the mean 5FU
half-life was found to be not significantly different (P =
0.75, paired t-test, mean ?/-SEM = 8.9 ?/-0.7 breathing
32 Cancer Chemother Pharmacol (2011) 68:29–36
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carbogen, 8.7 ?/-0.9 breathing air), and this approach was
not continued (see also [18] for two detailed case studies).
There was also no significant difference between the levels
of FNuct detected on the two scans (paired t-tests on semi-
quantitative values, contingency table test on positive/
negative classification). It has been proposed on the basis
of preclinical studies that the enhanced effect of 5FU in
combination with carbogen is a combination of two pro-
cesses: acidification by the CO2 component causing
increased intracellular/extracellular DpH (which has been
shown to increase 5FU uptake in isolated cells [19] and
experimental tumours [20]) and a trapping effect, where
tumour blood vessels open to allow increased blood flow
and then reclose, slowing the outflow of 5FU [10]. Such a
mechanism appears not to apply to normal liver, and thus
changes in tumour 5FU kinetics may be hidden by the
signal from normal liver. Howe et al [21] used 51Cr
radioactivity measurements to show that carbogen breath-
ing increased tumour blood volume in the GH3 prolacti-
noma grown in rats, but liver blood volume did not
Table 1 Clinical details, 5FU half-life values and progression-free survival (PFS) of patients
Patient Age Sex FU half-life (min)
(*with carbogen)
Liver mets FNuct PFS Months
A 73 M 8.9, 10.3* ? ? 2
B 60 M 11.9, 8.9* ? ? 1
C 62 M 15.5, 12.0* ? ? 1
D 64 M 6.9 - (liver cysts) ? 30?
E 79 M 9.4, 11.7* ? - 2
F 71 F 7.5, 8.08* ? ? 4
G 51 F 7.4 ? - 4
H 66 M 6.9 - - Adjuvant treatment. Discharged
at 5 years in full health
I 59 F 5.9, 6.5* ? - 3
J 71 F 11.8 ? - 3
K 67 M 5.5 - - 10
L 85 M 10.3 ? - 3
M 76 F 9.3 ? - 3
N 78 M 5.3 - - 5
O 67 M 6.3 - - 10
P 70 F 4.9 ? ? 3
Q 71 M 8.6 - - 2
R 67 F 6.8, 6.1* - ? 3
S 69 M 7.4, 6.8* ? - 5
T 47 M 5.3 ? - 5
U 74 M 11.4 - ? 6
V 79 F 5.9 ? - 17
W 67 F 4.8 - ? 9
X 59 M 8.0 ? - 14
Y 74 M 5.4 - ? 14
Z 54 F 9.5, 7.0* - ? 20
AA 68 M 9.6 - ? 72
BB 64 M 11.9 - - 7.5
CC 37 F 9.5 - - Adjuvant treatment. Discharged
at 8 years in full health
DD 69 F 4.0 - - Adjuvant treatment. Discharged
at 6 years in full health
EE 44 F 5.1 - - Adjuvant treatment. Discharged
at 5 years in full health
FF 74 F 7.7 - - 17
Mean ?/- sem 66?/-1.9 _ 8.0?/-0.48
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increase. Similarly, Honess and Bleehen [22] demonstrated
that carbogen breathing resulted in 50–70% increases in
perfusion in RIF-1 tumours and showed a smaller but
significant reduction of up to 20% in liver perfusion,
depending on the carbogen delivery rate; thus, an increased
5FU uptake in liver metastases could be masked by
simultaneous decreases in liver uptake. A recent PET study
with carbogen breathing of liver metastases in man [23]
demonstrated increased perfusion and specific uptake value
in metastases, accompanied by reduction in both parame-
ters in normal liver, although the total area under the curve
was not altered. van Laarhoven et al [24] demonstrated that
different colorectal tumour lines grown in mice respond
differently to carbogen; compared to the well-differentiated
C38 line, the poorly differentiated C26a showed smaller
changes in 5FU kinetics, but larger changes in response to
drug treatment, which the authors ascribe primarily to
vascular differences. Thus, the absence in our study of a
significant change of the 5FU half-life with carbogen
breathing, as measured over the whole liver, may not
necessarily mean that there was no change in the 5FU
kinetics in the metastases.
The previous observations of Wolf, Presant and co-
workers have demonstrated improved survival in a sub-
stantial subgroup of patients [2, 5], showing 5FU half-lives
longer than 20 min (5FU ‘‘trappers’’); 51 of their 99
evaluable subjects were classified as trappers, and 70% of
these responded to chemotherapy, while none of the non-
trappers responded to chemotherapy. None of the 32
patients in the present study had a half-life longer than
15.5 min, and thus, none of them would have fallen into
the ‘‘trapper’’ category. It is possible that this is in part due
to differences between the coil designs used in the work of
Wolf et al. and that used in the present study. The present
study used a large coil (16 9 20 cm) sensitive to the entire
liver volume; the work of Wolf et al. used surface coils of
3, 7 or 15 cm in diameter, and the ‘‘surface coil most
suitable to each patient’s study was selected, the choice
being dictated by the size of the tumour and its distance
from the skin’’ [5]. It is possible that a smaller probe more
tightly coupled to a superficial liver metastasis would be
more revealing of the tumour-specific pharmacokinetics
than the larger coil used in the study presented here.
Another explanation for the difference could be a different
patient population; it may be that 5FU was administered to
a group of patients with more advanced and/or less che-
mosensitive cancer in the present study, so that none of
them achieved the responses found by Wolf et al. In
addition, Wolf et al. studied some patients with primary
breast cancer and other unspecified cancers as well as those
with liver metastases; the responses are not broken down
by tumour type.
Fluoronucleotide signals
There was no significant difference in the mean FNuct
levels between the patients with liver metastases
Fig. 2 a Progression-free survival for patients with and without
metastatic liver disease. b Progression-free survival for patients with
metastatic disease, divided by the presence or absence of FNuct in
their summed 19F spectra. Detection of FNuct is associated with
poorer survival
Table 2 The fractional metastatic signal in the subset of patients
with metastatic disease for whom interpretable T2-weighted MRI data
were available (n=10)
Patient FU Half-life (min) FMS Mets
A 8.9 0.05 ?
B 11.9 0.05 ?
C 15.5 0.49 ?
E 9.4 0.52 ?
F 7.5 0.19 ?
G 7.4 0.10 ?
I 5.9 0.21 ?
J 11.8 0.05 ?
M 9.3 0.27 ?
P 4.9 0.19 ?
The FMS is the fraction of detected 19F signal which would result
from metastases if 5FU and its metabolites were distributed uniformly
throughout the liver and metastases
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(mets ? (n = 15) 0.49 ± 0.12,) and those without (mets-
(n = 17), 0.59 ± 0.14, P = 0.61). Overall, these data
suggest that patients vary greatly in FNuct level, but that
substantial amounts of FNuct are generated in normal liver
in some patients; detailed illustrative case studies of
hepatic FNuct signals in two early patients from this study
group in whom we verified the absence of liver metastases
were previously presented in [16].
Table 1 shows the PFS and FNuct data for each patient,
and Fig. 2a shows survival plots of the PFS for the groups
with and without liver metastases. Figure 2b shows sur-
vival plots for PFS for patients with metastatic disease
grouped by the presence or absence of FNuct in their
averaged spectra. Remarkably, in this group of patients, the
presence of FNuct in the spectra was associated with
poorer outcome, measured as PFS (P = 0.027). This is
unexpected, as the presence of high levels of cytotoxic
FNuct would intuitively be expected to result in higher cell
kill and better outcome.
To analyse this further, we calculated correlations
between PFS, FNuct level, FMS and 5FU half-life in
the metastasis-positive group (Table 3). FMS values are
available for only half of the cases. Intriguingly, the cor-
relations between FNuct and the other three parameters are
large, though only the positive correlation between FNuct
and 5FU half-life is significant (P = 0.016). The trend
towards a negative correlation between FNuct and PFS is
consistent with the poorer survival in the FNuct-positive
group of patients. A plausible hypothesis is that in the
metastasis-positive group, the level of FNuct is dominated
by the volume of metastasis, and larger volumes of
metastasis are correlated with poorer survival. In the met-
free group, in contrast, the level of FNuct might relate to
the levels of relevant enzymes in normal liver cells.
In conclusion, with the large coil used in this study, it
is possible to detect FNuct in liver and tumour tissue. The
similarity of 5FU half-life in patients with and without
liver metastases suggests that the observed signal may be
dominated by normal liver metabolism except when the
metastatic load is very high; notably, the two subjects
with the highest FMS values had long 5FU half-lives.
Within the patient group with liver metastases, FNuct
signal is positively correlated with 5FU half-life. There is
no clear association between 5FU half-life and outcome,
and the 5FU half-lives observed in this study are shorter
than those associated with improved outcome in the lit-
erature. Overall, these results suggest that metabolism of
5FU in normal liver is confounding any association
between half-life and treatment response in the data. High
FNuct levels appear to be associated with poorer outcome
as measured by PFS; this is likely to reflect higher met-
astatic load since FNuct is more likely to be produced in
tumour cells.
The use of 3T or higher power magnets should in
future facilitate such studies by reducing the minimum
volume of interest that can be studied and by permitting
the use of localised MRS methods. A localised 19F MRS
study at both 1.5T and 3T on the metabolism of cape-
citabine (a pro-drug of 5FU) in liver metastases from
colorectal cancer has been reported [25]. Magnetic reso-
nance spectroscopic imaging was used at both field
strengths to acquire a 3D grid of 8 9 8 9 8 voxels, with
each voxel of 4 9 4 9 4 cm. No FNuct signals were
reported, but the 3T spectra had clearly improved signal/
noise compared to the 1.5T spectra. The same group
subsequently published a capecitabine study at 3T with
absolute quantitation of 19F CSI data, using water 1H CSI
data acquired from the same coil tuned to 1H [26],
demonstrating considerable heterogeneity of capecitabine
and its metabolites even within normal liver. An approach
of this kind should make it possible to assess tumour 5FU
kinetics with minimal contamination from normal liver;
this would allow, for example, accurate assessment of the
effect of carbogen breathing on 5FU kinetics in the
tumour, and aggregating signals from multiple voxels
may allow comparison of FNuct levels in tumour and
normal liver. However, our current results suggest that
there may still be a useful role for non-localised 19F
spectroscopy as a prognostic marker, by enabling the
straightforward detection of FNuct, which is present at
very low concentrations distributed throughout the tissue.
Acknowledgments We would like to acknowledge the support of
The University of Cambridge, Cancer Research UK and Hutchison
Whampoa Limited. The MRUI software package was kindly provided
by the participants of the EU Network programmes: Human Capital
and Mobility, CHRX-CT94-0432 and Training and Mobility of
Researchers, ERB-FMRX-CT970160.u. The patient studies would not
Table 3 (a) P-values (b) Pearson r-values for correlations between
half-life, progression-free survival, FNuct levels (measured as FNuct/
peak 5FU) and fractional metastasis signal in the patient group with
liver metastatic disease
Half-life PFS FNuct FMS
a
Half-life 0.17 0.016 0.25
PFS 0.17 0.14 0.38
FNuct 0.016 0.14 0.09
FMS 0.25 0.38 0.09
b
Half-life -0.38 0.61 0.40
PFS -0.38 -0.40 -0.32
FNuct 0.61 -0.40 0.56
FMS 0.40 -0.32 0.56
Cancer Chemother Pharmacol (2011) 68:29–36 35
123
have been possible without the hard work of our research nurse,
Natasha Price.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Segal NH, Saltz LB (2009) Evolving treatment of advanced colon
cancer. Annu Rev Med 60:207–219
2. Presant CA, Wolf W, Waluch V, Wiseman C, Kennedy P,
Blayney D, Brechner RR (1994) Association of intratumoral
pharmacokinetics of fluorouracil with clinical response. Lancet
343:1184–1187
3. Findlay MPN, Raynaud F, Cunningham D, Iveson A, Collins DJ,
Leach MO (1996) Measurement of plasma 5-fluorouracil by high-
performance liquid chromatography with comparison of results to
tissue drug levels observed using in vivo 19F magnetic resonance
spectroscopy in patients on a protracted venous infusion with or
without interferon-a. Ann Oncol 7:47–53
4. Wolf W, Presant CA, Servis KL, El-Tahtawy A, Albright MJ,
Barker PB, Ring R III, Atkinson D, Ong R, King M, Singh M,
Ray M, Wiseman C, Blayney D, Shani J (1990) Tumor trapping
of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacoki-
netics in tumor-bearing humans and rabbits. Proceedings of the
National Academy of Sciences 87:492–496
5. Wolf W, Waluch V, Presant CA (1998) Non-invasive F-19-
NMRS of 5-fluorouracil in pharmacokinetics and pharmacody-
namic studies. NMR Biomed 11:380–387
6. Wolf W, Presant CA, Waluch V (2000) 19F-MRS studies of
fluorinated drugs in humans. Adv Drug Deliv Rev 41:55–74
7. Kamm YJL, Heerschap A, van den Bergh EJ, Wagener DJT
(2004) 19F-magnetic resonance spectroscopy in patients with
liver metastases of colorectal cancer treated with 5-fluorouracil.
Anti-Cancer Drugs 15:229–233
8. van Laarhoven HWM, Klomp DWJ, Rijpkema M, Kamm YLM,
Wagener DJT, Barentsz JO, Punt CJA, Heerschap A (2007)
Prediction of chemotherapeutic response of colorectal liver
metastases with dynamic gadolinium-DTPA-enhanced MRI and
localized 19F MRS pharmacokinetic studies of 5-fluorouracil.
NMR Biomed 20:128–140
9. Stevens AN, Morris PG, Iles RA, Sheldon PW, Griffiths JR
(1984) 5-fluorouracil metabolism monitored in vivo by 19F
NMR. Br J Cancer 50:113–117
10. McSheehy PMJ, Robinson SP, Ojugo ASE, Aboagye EO, Cannell
MB, Leach MO, Judson IR, Griffiths JR (1998) Carbogen
breathing increases 5-fluorouracil uptake and cytotoxicity in
hypoxic murine RIF-1 tumors: a magnetic resonance study in
vivo. Cancer Res 58:1185–1194
11. Sijens PE, Huang Y, Baldwin NJ, Ng TC (1991) 19F Magnetic
resonance spectroscopy studies of the metabolism of 5-fluoro-
uracil in murine rif-1 tumors and liver. Cancer Res 51:1384–1390
12. McSheehy PM, Prior MJ, Griffiths JR (1989) Prediction of 5-
fluorouracil cytotoxicity towards the Walker carcinosarcoma
using peak integrals of fluoronucleotides measured by MRS in
vivo. Br J Cancer 60:303–309
13. Doi Y, Shimmura T, Kuribayashi H, Tanaka Y, Kanazawa Y
(2009) Quantitative 19F imaging of nmol-level F-nucleotides/-
sides from 5-FU with T2 mapping in mice at 9.4T. Magn Reson
Med 62:1129–1139
14. Findlay MP, Leach MO (1994) In vivo monitoring of fluoro-
pyrimidine metabolites: magnetic resonance spectroscopy in the
evaluation of 5-fluorouracil. Anti-Cancer Drugs 5:260–280
15. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de
Beer R, Graveron-Demilly D (2001) Java-based graphical user
interface for the MRUI quantitation package. MAGMA
12:141–152
16. Vanhamme L, van den Boogaart A, Van Huffel S (1997)
Improved method for accurate and efficient quantification of
MRS data with use of prior knowledge. J Magn Reson 129:35–43
17. Kamm YJL, Heerschap A, Wagener DJT (2000) Effect of carb-
ogen breathing on the pharmacodynamics of 5-fluorouracil in a
murine colon carcinoma. Eur J Cancer 36:1180–1186
18. Griffiths JR, McIntyre DJO, Howe FA, McSheehy PMJ, Ojugo
ASE, Rodrigues LM, Wadsworth P, Price NM, Lofts F,
Nicholson G, Smid K, Noordhuis P, Peters GJ, Stubbs M (2001)
Issues of normal tissue toxicity in patient and animal studies—
Effect of carbogen breathing in rats after 5-fluorouracil treatment.
Acta Oncol 40:609–614
19. Ojugo ASE, McSheehy PMJ, Stubbs M, Alder G, Bashford CL,
Maxwell RJ, Leach MO, Judson IR, Griffiths JR (1998) Influence
of pH on the uptake of 5-fluorouracil into isolated tumour cells.
Br J Cancer 77:873–879
20. Guerquin-Kern J-L, Leteurtre F, Croisy A, Lhoste J-M (1991) pH
Dependence of 5-fluorouracil uptake observed by in vivo 31p and
19f nuclear magnetic resonance spectroscopy. Cancer Res
51:5770–5773
21. Howe FA, Robinson SP, Rodrigues LM, Griffiths JR (1999) Flow
and oxygenation dependent (FLOOD) contrast MR imaging to
monitor the response of rat tumors to carbogen breathing. Magn
Reson Imaging 17:1307–1318
22. Honess DJ, Bleehen NM (1995) Perfusion changes in the RIF-1
tumour and normal tissues after carbogen and nicotinamide,
individually and combined. Br J Cancer 71:1175–1180
23. Gupta N, Saleem A, Kotz B, Osman S, Aboagye EO, Phillips R,
Vernon C, Wasan H, Jones T, Hoskin PJ, Price PM (2006)
Carbogen and nicotinamide increase blood flow and 5-fluoro-
uracil delivery but not 5-fluorouracil retention in colorectal can-
cer metastases in patients. Clin Cancer Res 12:3115–3123
24. van Laarhoven HWM, Gambarota G, Lok J, Lammens M, Kamm
YLM, Wagener T, Punt CJA, van der Kogelz AJ, Heerschap A
(2006) Carbogen breathing differentially enhances blood plasma
volume and 5-fluorouracil uptake in two murine colon tumor
models with a distinct vascular structure. Neoplasia 8:477–487
25. van Laarhoven HWM, Klomp DWJ, Kamm YJL, Punt CJA,
Heerschap A (2003) In vivo monitoring of capecitabine metab-
olism in human liver by 19fluorine magnetic resonance spec-
troscopy at 1.5 and 3 tesla field strength. Cancer Res
63:7609–7612
26. Klomp DWJ, van Laarhoven HWM, Scheenen T, Kamm YJL,
Heerschap A (2007) Quantitative 19F MR spectroscopy at 3 T to
detect heterogeneous capecitabine metabolism in human liver.
NMR Biomed 20:485–492
36 Cancer Chemother Pharmacol (2011) 68:29–36
123
